News
Digital health platform to introduce family-building benefits programme
More companies than ever are providing benefits that cover procedures such as IVF, egg freezing and surrogacy
The US digital health platform Ovia Health is to introduce its first fertility and family-building benefits programme in an effort to better support employees.
The new offerings would allow employers and health plans to design plan benefits and assistance packages based on their specific goals and budgets.
The solution is hoped to extend Ovia’s approach to support family journeys, including through assisted reproductive technologies (ART), adoption and surrogacy, and will be available to members of all demographics and family types, including those of same-sex couples and individuals.
“Compared to existing fertility point solutions that approach fertility health as a single point in time, we designed our fertility and family-building benefit to offer employers and health plans a customisable solution to help engage and support their employees and health plan members during their entire family-building journey – from preconception and pregnancy to postpartum and beyond,” said Dr Leslie Saltzman, Ovia’s chief medical officer.
More companies than ever are providing benefits that cover procedures such as IVF, egg freezing and surrogacy.
According to a 2023 report by the Chartered Institute of Personnel Development, around half (49 per cent) of employers surveyed provide some kind of support for employees pursuing fertility treatment.
Ovia’s fertility benefits programme would include a financial tool allowing employers to contribute funds designated for eligible family-building services, support for members to identify and navigate fertility clinics, providers and surrogacy and adoption agencies and one-on-one support and clinical guidance from the company’s in-house care team.
Dr Jenny Carrillo, president of Ovia, said: “As individuals and families increasingly pursue fertility, adoption and surrogacy to build their families, many feel isolated or unequipped to navigate these processes themselves.
“We believe our new fertility and family-building benefit is a key step toward improving health equity, providing greater access and support for families on their family-building journeys.”
The Ovia fertility and family-building benefit programme is set to launch in January next year.
To receive the Femtech World newsletter, sign up here.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






